促肾上腺皮质激素细胞腺瘤中MGMT表达异质性及替莫唑胺获得性耐药机制
该研究对25例促肾上腺皮质激素细胞肿瘤进行MGMT免疫组化分析,发现80%的肿瘤存在显著的瘤间和瘤内异质性。体外建立高剂量和低剂量替莫唑胺诱导的耐药AtT20细胞模型,耐药细胞对替莫唑胺生长抑制的敏感性分别下降6.3倍和3.4倍,且MGMT mRNA和蛋白表达升高、MGMT阳性细胞数增加1.8倍,但MGMT启动子甲基化水平无差异。结论提示高表达MGMT细胞的克隆选择可能参与获得性耐药。
要点
- 80%的促肾上腺皮质激素细胞肿瘤存在MGMT表达的瘤间和瘤内异质性。
- 高剂量和低剂量替莫唑胺诱导的耐药细胞敏感性分别下降6.3倍和3.4倍。
- 耐药细胞MGMT mRNA和蛋白表达升高,MGMT阳性细胞数增加1.8倍,启动子甲基化无差异。
核心结论
- 促肾上腺皮质激素细胞垂体肿瘤中MGMT表达存在高度瘤间和瘤内异质性。
- 在获得性替莫唑胺耐药的促肾上腺皮质激素垂体肿瘤细胞模型中,耐药与MGMT表达和MGMT阳性细胞百分比显著增加相关。
- 推测高表达MGMT细胞的克隆选择参与获得性替莫唑胺耐药。
研究设计与样本
- 对25例促肾上腺皮质激素肿瘤进行MGMT免疫组化分析以评估瘤内异质性。
- 体外建立AtT20促肾上腺皮质激素肿瘤细胞模型,分别经高剂量和低剂量替莫唑胺暴露后获得耐药,低剂量代表临床可达浓度。
主要发现
- 80%的肿瘤显示MGMT免疫染色存在显著的瘤间和瘤内异质性分布。
- 高剂量和低剂量替莫唑胺诱导的耐药细胞对替莫唑胺生长抑制作用的敏感性分别下降6.3倍和3.4倍。
- 耐药细胞中替莫唑胺诱导的细胞周期相位变化低于对照细胞。
- 耐药细胞MGMT mRNA和蛋白表达更高,MGMT阳性细胞数增加1.8倍。
- MGMT启动子甲基化水平无差异。
临床怎么用
- 对于替莫唑胺治疗后复发的促肾上腺皮质激素细胞肿瘤,需考虑MGMT表达异质性及获得性耐药。
- MGMT免疫组化可评估肿瘤内异质性,但需注意取样代表性。
- 低剂量替莫唑胺暴露亦可诱导耐药,提示临床用药方案需关注耐药风险。
局限性
- 免疫组化分析样本量较小(25例肿瘤)。
- 体外模型结果需进一步临床验证。
- 耐药机制仅为假设,未直接证明克隆选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Temozolomide (TMZ) can be an effective medical treatment for aggressive pituitary tumors. In case of disease recurrence following TMZ treatment, however, treatment with the drug generally does not control tumor regrowth. OBJECTIVE: This work aimed to better understand the mechanisms of resistance of corticotroph tumors to TMZ in the context of heterogeneity of methylguanine-DNA methyltransferase (MGMT) expression. METHODS: We performed immunohistochemical analysis of the MGMT expression pattern in 25 corticotroph tumors to evaluate intratumoral heterogeneity. In addition, we created in vitro models of AtT20 corticotroph tumor cells with acquired TMZ-resistance after exposure to high- and low-dose TMZ, the latter representing a clinically achievable TMZ level. RESULTS: MGMT immunostaining in corticotroph tumors showed a considerable heterogeneous intertumoral and intratumoral distribution pattern in 80% of tumors. In the in vitro model, high- and low-dose TMZ challenges induced a 6.3- and 3.4-fold decreased sensitivity to the growth inhibitory effect of TMZ. TMZ-induced changes in cell cycle phases were lower in TMZ-resistant cells than in vehicle-challenged cells. TMZ-resistant cells had higher Mgmt messenger RNA and protein expression and 1.8-fold higher number of Mgmt-positive cells. No difference was observed in the level of Mgmt promoter methylation. CONCLUSION: Corticotroph pituitary tumors demonstrate a high intertumoral and intratumoral heterogeneity in MGMT expression. In an acquired TMZ-resistant corticotroph pituitary tumor cell model, TMZ resistance was associated with strong increase in MGMT expression and percentage of MGMT-positive cells. We hypothesize that clonal selection of high MGMT-expressing cells is involved in this acquired TMZ resistance.
引用
- Paes T, Feelders RA, Dogan F, et al. Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance. J Clin Endocrinol Metab. 2026. PMID: 42149504. doi:10.1210/clinem/dgag170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。